TY - CHAP M1 - Book, Section TI - Diagnosis and Management of Heart Failure with Preserved Ejection Fraction – Updated April 2023 A1 - Ferreira, João Pedro A1 - Sharma, Kavita A1 - Butler, Javed A2 - Fuster, Valentin A2 - Narula, Jagat A2 - Vaishnava, Prashant A2 - Leon, Martin B. A2 - Callans, David J. A2 - Rumsfeld, John S. A2 - Poppas, Athena Y1 - 2022 N1 - T2 - Fuster and Hurst's The Heart, 15e AB - Content UpdateSemaglutide in Patients with Heart failure with Preserved Ejection Fraction and Obesity: a New Addition to the Armamentarium of Heart Failure TherapiesThe STEP-HFpEF Trial was a phase 3 clinical trial designed to assess the impact of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP1ra), on both heart failure quality-of-life metrics and reduction in weight in those with heart failure with preserved ejection fraction (HFpEF) and obesity. Read More SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesscardiology.mhmedical.com/content.aspx?aid=1204744812 ER -